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CLINICAL RESEARCH
Valvular heart disease
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Aims To analyse the effectiveness of cardiac resynchronization therapy (CRT) in patients with valvular heart disease (a
subset not speciﬁcally investigated in randomized controlled trials) in comparison with ischaemic heart disease or
dilated cardiomyopathy patients.
Methods
and results
Patients enrolled in a national registry were evaluated during a median follow-up of 16 months after CRT implant. Patients
with valvular heart disease treated with CRT (n ¼ 108) in comparison with ischaemic heart disease (n ¼ 737) and dilated
cardiomyopathy (n ¼ 635) patients presented: (i) a higher prevalence of chronic atrial ﬁbrillation, with atrioventricular
node ablation performed in around half of the cases; (ii) a similar clinical and echocardiographic proﬁle at baseline;
(iii) a similar improvement of LVEF and a similar reduction in ventricular volumes at 6–12 months; (iv) a favourable clinical
response at 12 months with an improvement of the clinical composite score similar to that occurring in patients with
dilated cardiomyopathy and more pronounced than that observed in patients with ischaemic heart disease; (v) a long-
term outcome, in term of freedom from death or heart transplantation, similar to patients affected by ischaemic
heart disease and basically more severe than that of patients affected by dilated cardiomyopathy.
Conclusion In ‘real world’ clinical practice, CRT appears to be effective also in patients with valvular heart disease. However, in
this group of patients the outcome after CRT does not precisely overlap any of the two other groups of patients, for
which much more data are currently available.
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Heart failure may occur in the presence of a wide range of under-
lying heart diseases, including valvular heart disease, with or
without previous surgery. It is well known that the clinical proﬁle
of patients enrolled in randomized clinical trials may be quite differ-
ent from the proﬁle of patients treated in daily clinical practice
1,2
and these differences may also exist with regard to non-
pharmacological treatments such as cardiac resynchronization
therapy (CRT). Indeed, in most of the major randomized clinical
trials that validated the clinical use of CRT,
3–5 the presence of a
clinically signiﬁcant valvular heart disease or of previous valvular
surgery were speciﬁc exclusion criteria. Only CARE HF allowed
inclusion of patients with valvular heart disease, although excluding
those in chronic atrial ﬁbrillation; in this trial, patients with previous
valve replacement/repair or with valve-related heart failure
accounted for 7% of enrolled patients, but the outcome of this
group has never been reported separately from the whole popu-
lation.
6 Moreover, all the major randomized clinical trials on
CRT excluded the enrolment of patients with chronic permanent
atrial ﬁbrillation, an arrhythmia which is frequently associated with
valvular heart disease, and it is known that atrial ﬁbrillation and its
management may affect the efﬁcacy of CRT and patients’ progno-
sis.
7,8 According to these considerations, we do not at present
have speciﬁc trial-derived information on the impact of CRT in
patients with valvular heart disease. Observational registries
may provide useful information on the number of patients with
valvular heart disease receiving CRT in ‘real-world’ clinical practice,
with or without associated atrial ﬁbrillation, as well as on their
outcome. The aim of the present study was to analyse the
proportion of patients with valvular heart disease or previous
valvular surgery receiving CRT in a large national registry and to
compare the outcome of these patients with the outcome of
patients with dilated cardiomyopathy or ischaemic heart disease
treated with CRT.
Methods
Between 1999 and 2005, patients successfully implanted in Italy with
biventricular pacing devices for CRT delivery, with (CRT-D) or
without (CRT-P) deﬁbrillator capability (CRT models 8040, 8042;
CRT-D models 7272, 7277, 7279, Medtronic Inc., Minneapolis, MN,
USA) were enrolled in the InSync/InSync ICD Italian Registry. The Reg-
istry enrolled patients with mild or severe symptomatic chronic HF
(NYHA class II–IV) despite pharmacological therapy, an ejection frac-
tion (LVEF)  35% and a wide QRS complex (.130 ms). Patients with
recent myocardial infarction (,3 months) or with decompensated HF
were excluded. Informed consent approved by Local Ethics Commit-
tees was obtained from all patients.
For the current analysis, patients were classiﬁed, according to the
underlying heart disease, as being affected by valvular heart disease,
ischaemic heart disease, dilated cardiomyopathy, or a combination of
previous heart diseases. The assignment to the valvular heart disease
group was based on clinical history combined with evidence of clini-
cally signiﬁcant primary valvular disease (organic alterations of valvular
apparatus with at least moderate aortic or mitral regurgitation, the
latter not simply due to mitral annulus enlargement with normal leaf-
lets), or previous valve replacement or repair for organic valvular
disease, in the absence of other overt causes of left-ventricular
dysfunction. The assignment to the ischaemic heart disease group
was based on clinical history of prior myocardial infarction, prior per-
cutaneous coronary intervention, or prior coronary bypass surgery, or
evidence of clinically signiﬁcant coronary stenosis (at least 75% nar-
rowing of at least one of the three major coronary arteries), similarly
to the assignment used in large CRT trials.
3–6 Patients were classiﬁed
as affected by dilated cardiomyopathy, in the presence of a typical
pattern of this heart disease, without ischaemic or organic valvular
heart diseases as identiﬁable causative factors for heart failure. For
the aims of the current analysis, the following groups were considered:
(i) patients with valvular heart disease (and no evidence of coronary
artery disease); (ii) patients with ischaemic heart disease and no
history of primary disease or interventions; (iii) patients with dilated
cardiomyopathy. Patients enrolled in the registry but found to be
affected by a combination of heart diseases were not included in the
present analysis.
The devices and the pacing leads were implanted by means of
standard techniques
9 with the transvenous LV lead positioned in a
lateral or postero-lateral cardiac vein via the coronary sinus. When a
conventional indication for an implantable cardioverter deﬁbrillator
existed, a combined device was implanted. The baseline evaluation
included demographics and medical history, clinical examination,
12-lead electrocardiogram, estimation of NYHA functional class and
2-dimensional, M-mode, and Doppler echocardiography. Speciﬁcally,
the following parameters were collected: LV end-systolic and end-
diastolic diameters (LVESD and LVEDD, respectively), LV end-diastolic
and end-systolic volume (LVEDV and LVESV), LVEF assessed by Simp-
son’s equation using the apical four-chamber view.
10 The severity of
mitral regurgitation (from degree 1 to degree 4) was assessed by the
percent jet area relative to left atrial size in the apical four-chamber
view and, similarly, the severity of aortic regurgitation (from degree
1 to degree 4) was assessed by the area of regurgitant jet relative to
left-ventricular chamber.
Echo-directed adjustment of the atrio-ventricular pacing interval was
done before patients were discharged and at follow-up to optimize
haemodynamic function. Pharmacological treatments were based on
clinical evaluation by the attending physicians. Patients returned for
regular clinic visits at 1, 3, and 6 months and every 6 months thereafter.
Besides the clinical evaluation, 12-lead electrocardiogram, NYHA class,
and detailed device checks were performed at each follow-up visit. In
addition, standard echocardiography was performed at the 6 and 12
month follow-up visits in all patients.
The impact of CRT on clinical and echocardiography outcome was
evaluated comparing the baseline with 6 and 12 month follow-up data.
Moreover, at the 12 month follow-up patients were classiﬁed accord-
ing to a clinical composite score, which assigns subjects to one of three
response groups—improved, worsened, or unchanged—according to
a predeﬁned scheme.
11 A patient was deﬁned as ‘improved’ in the
case of a favourable change in NYHA class and neither hospitalization
due to worsening HF nor death during the observation period.
Mortality data were obtained by physicians’ or hospitals’ ﬁles review
or by direct telephone contact. Events were classiﬁed as cardiac death
(deﬁned as sudden or non-sudden cardiac deaths) and non-cardiac
death. According to the Hinkle–Thaler classiﬁcation,
12 sudden
cardiac death was deﬁned as abrupt, unexpected death occurring
within 1 h from the insurgence of symptoms. Non-sudden cardiac
death was mainly represented by progressive HF deﬁned as unstable,
clinical progression of deteriorating pump function in the setting of
active therapy, most often in an intensive care setting. All deaths not
complying with the aforementioned criteria were classiﬁed as non-
cardiac death.
12
G. Boriani et al. 2276Statistical analysis
Continuous data were expressed as means+standard deviation. Cat-
egorical data were expressed by percentages. Differences between
mean data were compared by a t-test for Gaussian variables, and by
the Mann–Whitney or Wilcoxon non-parametric test for non-
Gaussian variables, respectively, for independent or paired samples.
Differences in proportions were compared by a x
2 analysis or
Fisher’s exact test, as appropriate. Multiple comparisons were per-
formed with the Bonferroni correction. For the comparison with base-
line, 6 and 12 month clinical and echocardiographic values were
considered for surviving patients, otherwise the last observation was
carried forward. Mortality rate was summarized by construction of
Kaplan–Meier curves and the distributions of the groups were com-
pared by a log-rank test. A P-value , 0.05 was considered signiﬁcant
for all tests. All statistical analyses were performed using SPSS software
(SPSS Inc., Chicago, IL, USA).
Results
Patient population
The overall population of 1844 patients enrolled and followed in
the InSync/InSync ICD Italian Registry was analysed; after exclusion
of cases with a combination of underlying heart diseases,
1480 patients fulﬁlled the criteria for the present analysis. In par-
ticular, 108 presented with dilated cardiomyopathy of valvular
aetiology and no evidence of coronary artery disease; in 737
patients the primary cause of heart failure was coronary artery
disease and no valvular heart disease was diagnosed, while for
the remaining 635 patients the investigators reported a diagnosis
of dilated cardiomyopathy.
The median [25–75 percentile] follow-up was 16 [9–26]
months, and was comparable in the three groups. The demo-
graphics, baseline clinical parameters, and pharmacological
therapy are listed in Table 1.
In the group of patients with valvular heart disease, 50 had suf-
fered lone aortic insufﬁciency (previous surgical correction in 22
patients), 38 mitral insufﬁciency (corrected in 18), and the remain-
ing 20 combined aortic and mitral valvular regurgitation (combined
aortic and mitral correction in 12, aortic correction in 2), for a
median of 24 [8–50] months. No patient presented a signiﬁcant
(at least moderate) mitral or aortic stenosis at the time of CRT
implant. For the 54 patients with a history of valve replacement
or repair, the median time from the operation to enrolment was
24 [12–48] months.
A device with deﬁbrillator capability (CRTD) was implanted only
in 17 (16%) patients with valvular heart disease, with respect to
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 1 Demographics, baseline clinical parameters, and pharmacological treatment of the three groups of patients
Parameter Valvular HD (n 5 108) Ischaemic HD (n 5 737) Dilated CMP (n 5 635)
Male gender, n (%) 87 (81) 662 (90)* 460 (72)**
Age, years 66+10 69+8* 66+10**
Hospitalizations for HF (prior 12 months), n/year 2.0+1.5 1.7+1.6 1.6+1.4
Chronic atrial ﬁbrillation, n (%) 40 (37) 88 (12)* 106 (17)*, **
QRS duration, ms 170+33 163+32 165+30
NYHA class
Class II 16 (15) 140 (19) 121 (19)
Class III 71 (66) 494 (67) 419 (66)
Class IV 21 (19) 103 (14) 95 (15)
LVEF,% 27+72 6 +72 6 +7
LVEDD, mm 70+86 9 +96 9 +10
LVESD, mm 60+11 57+10 59+11
LVEDV, mL 257+61 227+85 223+118
LVESV, mL 172+60 155+79 147+93
Mitral regurgitation, degree 2.2+1.2 2.1+0.9 2.1+1.0
CRT-D use, n (%) 17 (16) 447 (61)* 212 (33)*, **
Secondary prevention, n (%) 12 (11) 229 (31)* 125 (20)**
Diuretic use, n (%) 94 (87) 635 (86) 565 (89)
ACE-inhibitors or ARB use, n (%) 82 (76) 517 (70) 473 (74)
b-Blockers use, n (%) 45 (42) 345 (47) 334 (53)
Class III antiarrhythmics use, n (%) 38 (35) 287 (39) 208 (33)**
Nitrates use, n (%) 8 (7) 221 (30)* 92 (14)**
CMP, cardiomyopathy; HD, heart disease; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter;
LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; ACE, angiotensin-converting-enzyme; ARB, angiotensin-receptor blockers.
*P-value , 0.05 vs. valvular HD.
**P-value , 0.05 vs. ischaemic HD (Bonferroni-corrected).
Cardiac resynchronization in valvular disease 2277447 patients (61%) in the group with ischaemic heart disease and
212 (33%) in the group affected by dilated cardiomyopathy (P ,
0.001 for all comparisons). The proportion of patients implanted
with a CRTD device increased over time in all three groups of
patients (in 1998–2001 CRTD accounted for 13, 38, and 24% of
the implants performed in patients with valvular heart disease,
ischaemic heart disease and dilated cardiomyopathy, respectively,
while the same ﬁgures in 2004–2005 increased to 43, 75, and
39%, respectively).
As shown in Table 1, a series of clinical and echocardiographic
characteristics were comparable among the three groups.
A higher prevalence of males and a higher mean age was observed
in the group with ischaemic heart disease with respect to the other
two groups, whereas a signiﬁcantly higher proportion of patients
with valvular heart disease were in chronic atrial ﬁbrillation at
the time of device implant. Among the patients with chronic
atrial ﬁbrillation, atrioventricular junction ablation was performed
at the time of implant, or within 2 months, in 18 out of 40 patients
(45%) with valvular heart disease, 46 out of 88 patients (52%) with
ischaemic heart disease, and 49 out of 106 patients (46%) with
dilated cardiomyopathy.
Effects on clinical outcomes and on
echocardiographic parameters
The comparison of clinical and echocardiographic parameters
recorded at baseline and during CRT, at the 6 and 12 month
follow-up visits is reported in Table 2 for the three groups of
patients. At the 6 month follow-up, a signiﬁcant improvement in
NYHA functional class was observed in all groups. In all patients,
the mean QRS duration during pacing was signiﬁcantly decreased
in comparison with baseline spontaneous QRS, and an increase
of LVEF occurred with signiﬁcant reductions of LVEDD and
LVESD. Left-ventricular end-diastolic volume appeared signiﬁcantly
decreased only for patients with dilated cardiomyopathy, whereas
a reduction of LVESV was apparent for both the group of patients
with valvular heart disease and the group with dilated cardiomyo-
pathy, but not for patients with ischaemic heart disease. All these
changes persisted at the 12 month follow-up visit.
The effects of CRT on clinical and echocardiographic variables
was also analysed within the group of patients with valvular HD,
by stratifying the patients according to the severity of mitral regur-
gitation at baseline (, or  3 at baseline, respectively). As shown
in Table 3, both subgroups showed improvement in NYHA class
and LVEF, but with a different effect on mitral regurgitation (a sig-
niﬁcant reduction was observed in patients with more severe
mitral regurgitation at baseline).
The response to CRT at the 12 month follow-up, measured
according to the aforementioned clinical composite score, is
reported in Figure 1 for the three study groups, taking into
account the overall population (Figure 1A) and only patients in
NYHA class III and IV (Figure 1B), respectively. Speciﬁcally, in the
whole population 74 patients in the group with valvular heart
disease (69%) were deﬁned as ‘improved’, with respect to 399
patients with dilated cardiomyopathy (63%, P¼NS vs. valvular
heart disease) and 419 patients with ischaemic heart disease
(57%, P ¼ 0.022 vs. valvular and P ¼ 0.024 vs. dilated
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G. Boriani et al. 2278cardiomyopathy patients). Speciﬁcally, among the components of
the clinical composite score, a favourable change in NYHA class
was observed, in the whole population, in 82 patients (76%) in
the group with valvular heart disease, in 465 patients (63%) with
ischaemic heart disease (P ¼ 0.009 vs. valvular heart disease),
and in 433 patients (68%) with dilated cardiomyopathy (P ¼
0.107 vs. valvular heart disease). The pattern of response in the
analysis performed in NYHA class III and IV patients proved to
be similar to the previous response pattern, although with slightly
higher improvement rates (Figure 1B).
In the whole study population, 166 of 1480 patients died or
underwent urgent heart transplantation (rate 7.3 per 100 patient-
years of follow-up). There were 17 deaths in the group with valv-
ular heart disease (rate 8.8 per 100 patient-years of follow-up),
96 deaths in the group with ischaemic heart disease (rate 8.7 per
100 patient-years of follow-up), and 53 deaths in the group with
dilated cardiomyopathy (rate 5.3 per 100 patient-years of
follow-up, P ¼ 0.005 vs. ischaemic group).
The survival curves for all-cause mortality or heart transplan-
tation obtained by Kaplan–Meier analysis are shown in Figure 2,
for both the overall population (Figure 2A) and the patients with
NYHA class III-IV at device implant (Figure 2B). In the overall popu-
lation the survival curve of patients with ischaemic heart disease
differed from that of patients with dilated cardiomyopathy
(Log-rank test, P ¼ 0.004), and the worse prognosis of patients
with ischaemic heart disease was conﬁrmed in the analysis of
NYHA class III–IV patients.
A series of factors were analysed by univariate and multivariate
logistic regression analysis as predictors of death from any cause or
urgent heart transplantation: chronic atrial ﬁbrillation, not treated
with atrioventricular node ablation, signiﬁcantly increased the
risk, while beta-blocker use proved to have a signiﬁcant protective
role in the whole patient population (Table 4). Among patients
with valvular heart disease or dilated cardiomyopathy, the only
independent predictor of death from any cause or urgent heart
transplantation was chronic atrial ﬁbrillation, not treated with
atrioventricular node ablation (Table 5).
A total of 168 patients had at least one hospitalization for wor-
sening HF, 13 were in the group with valvular heart disease (rate
..................................................... .....................................................
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Table 3 Clinical and echocardiographic parameters at baseline and 6 month follow-up for the group of patients with
valvular heart disease, stratiﬁed according to the degree of mitral regurgitation at baseline, <3 (73 patients of whom 28
with previous mitral surgery) and  3 (35 patients of whom two with previous mitral surgery), respectively
Parameter Patients with valvular heart disease and
mitral regurgitation degree <3a t
baseline (n 5 73)
Patients with valvular heart disease and
mitral regurgitation degree  3a t
baseline (n 5 35)
Baseline 6 month follow-up Baseline 6 month follow-up
QRS duration, ms 168+31 147+27*** 186+40 159+31***
NYHA class 3.1+0.6 2.1+0.6*** 2.9+0.5 1.9+0.5***
LVEF,% 27+73 4 +9*** 25+73 3 +7*
LVEDD, mm 70+86 5 +11* 71+86 9 +13
LVESD, mm 60+11 53+14* 59+10 57+13
LVEDV, mL 257+62 200+81* 257+63 259+70
LVESV, mL 174+43 125+56** 169+89 160+90
Mitral regurgitation, degree 1.5+0.5 1.7+0.8 3.7+0.5 2.7+0.9*
*P-value ,0.05 vs. baseline.
**P-value ,0.01 vs. baseline.
***P-value ,0.001 vs. baseline.
Figure 1 Response to cardiac resynchronization therapy
according to the clinical composite score in the whole patient
population (A) or only in patients with NYHA functional class
III–IV at baseline (B), according to the underlying heart disease.
Cardiac resynchronization in valvular disease 22796.7 per 100 patient-years of follow-up), 96 in the group with
ischaemic heart disease (rate 8.7 per 100 patient-years of
follow-up), and 59 in the group affected by dilated cardiomyopathy
(rate 6.0 per 100 patient-years of follow-up, all P ¼ NS).
Discussion
The impact of CRT on symptoms and survival in the speciﬁc setting
of heart failure patients with underlying valvular heart disease has
not been previously investigated. In our registry, 5.9% of the
patients treated with CRT had a valvular heart disease as the
primary and sole cause of heart failure, as evaluated by attending
physicians.
A series of considerations linked to patients’ characteristics and
pathophysiological issues make it interesting to assess the effective-
ness of CRT in this subset of patients in comparison with patients
affected by ischaemic heart disease and dilated cardiomyopathy,
the two subsets of patients in whom the efﬁcacy of CRT has
already been validated by a series of randomized controlled
trials.
13 These considerations include: the consequences of a
potentially increased prevalence of chronic atrial ﬁbrillation and
the unknown effects of biventricular pacing on ventricular
volumes in the presence of some degree of volume overload
due to aortic valve insufﬁciency, or mitral regurgitation, with or
without surgical correction.
The present study shows that in daily clinical practice, where the
strict exclusion criteria of randomized clinical trials are not applied,
patients with valvular heart disease represent a relatively small min-
ority of CRT recipients, with both some similarities and some dis-
tinct features in comparison to patients with ischaemic heart
disease or dilated cardiomyopathy. According to our ﬁndings,
chronic atrial ﬁbrillation is much more common in patients with
valvular heart disease treated with CRT than in the other two
groups of underlying heart disease, being present in more than
one-third of the cases, with atrioventricular node ablation per-
formed in around half of the cases with chronic atrial ﬁbrillation.
It is expected that atrioventricular node ablation will be more
widely used in the future, as a way of ensuring constant ventricular
pacing during CRT (if the percentage of ventricular pacing is lower
Figure 2 Kaplan–Meier estimates of time to death from any
cause in the whole patient population (A) or only in patients
with NYHA functional class III–IV at baseline (B), according to
the underlying heart disease.
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Table 4 Univariate and multivariate analysis of factors predicting death from any cause or urgent heart transplantation
in the whole population (n 5 1480)
Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
Ischaemic heart disease 1.5 1.1–2.0 0.012 1.3 0.8–2.1 0.308
Male gender 1.7 1.1–2.7 0.027 1.2 0.7–2.3 0.481
Age 1.1 1.0–1.1 0.004 1.0 1.0–1.0 0.203
Chronic atrial ﬁbrillation (no AVN ablation) 1.6 1.1–2.3 0.021 1.8 1.1–3.2 0.030
Chronic atrial ﬁbrillation (AVN ablation) 1.0 0.5–1.4 0.612 — — —
QRS duration 1.0 0.9–1.0 0.711 — — —
NYHA class 1.1 0.8–1.4 0.691 — — —
LV ejection fraction 0.9 0.8–0.9 0.001 1.0 0.9–1.0 0.073
LVEDD 1.0 0.9–1.1 0.371 — — —
LVESD 1.0 0.9–1.1 0.347 — — —
Mitral regurgitation 1.2 0.9–1.5 0.069 1.2 1.0–1.6 0.077
CRT-D use 1.0 0.8–1.4 0.810 — — —
b-Blockers use 0.4 0.3–0.6 0.001 0.4 0.2–0.6 0.001
AVN, atrioventricular node.
G. Boriani et al. 2280than 85%) and as a way of improving patient outcome after CRT.
7,8
The present observational study stresses the role of atrioventricu-
lar node ablation as a factor linked to patient outcome, not only in
the usual setting of patients with ischaemic heart disease or dilated
cardiomyopathy but also in a less selected setting, taken from daily
clinical practice, also including patients with valvular heart disease.
In our analysis, the other clinical and echocardiographic character-
istics of valvular heart disease patients at baseline do not show
marked differences in comparison with the two other groups
and this is the basis for comparing the response to CRT, in
terms of echocardiographic changes and clinical effectiveness. In
our population sample, the response at 6 and 12 months of
follow-up appeared to be favourable in patients with valvular
heart disease, with a signiﬁcant improvement in NYHA functional
class and LVEF and a reduction in LV volumes, similarly to patients
affected by dilated cardiomyopathy or ischaemic heart disease. In
an observational, non-comparative study on 40 patients with
CRT in the setting of HF after corrective valvular surgery, Macias
et al.
14 recently reported an improvement of symptoms, functional
capacity and echocardiographic indices, on the basis of a 6 month
follow-up.
In the literature, various authors
15–17 have reported that the
response to CRT is different in ischaemic patients in comparison
to patients with dilated cardiomyopathy, but no data are available
on the response rate in patients with valvular heart disease. It is
noteworthy to consider that while the clinical response to CRT
at 12 months in patients with valvular heart disease appears to
be similar to the response rate of dilated cardiomyopathy patients,
the long-term outcome in terms of freedom from all-cause death
or heart transplantation is more similar to that of ischaemic heart
disease patients, with a trend towards a worse outcome in com-
parison with dilated cardiomyopathy patients. It can be argued
that the worse long-term outcome in comparison with dilated
cardiomyopathy may be due to progression of the underlying
disease with evolution of the haemodynamic load due to uncor-
rected or lately corrected valvular dysfunction. Larger population
samples should further address this topic, also considering the
speciﬁc outcome of various subgroups of patients with valvular
heart disease (i.e. mitral regurgitation, previous mitral repair,
mitral valve prosthesis, aortic insufﬁciency, aortic prosthesis, com-
bined valvular, and aortic diseases, etc.).
No randomized controlled trial has speciﬁcally evaluated the
effects of CRT in patients affected by a valvular heart disease,
but on the basis of the present observational study, where the
effectiveness of CRT in this particular subset of patients was com-
pared with the effectiveness of CRT in two settings (ischaemic
heart disease and dilated cardioyopathy) with a full validation of
CRT by randomized controlled trials, it appears worth to apply
CRT to similar patients with valvular heart disease. It should in
any case be stressed that patients with valvular heart disease
treated with CRT in daily clinical practice appear to have some dis-
tinct clinical features, as well as an overall response rate, by com-
bining clinical and structural changes (reverse remodelling) and
outcome that do not precisely overlap any of the two other
groups of patients, for which much more data are currently
available.
The data of the present study derive from an observational reg-
istry, with prospective collection of data according to a predeﬁned
scheme, including clinical and laboratory evaluations performed
before and after device implant, as well as periodic follow-up
visits and checks of the device system. This study therefore has
all the limitations of multicentre observational studies, such as
potential bias in patient selection and the lack of a control
group. The study also included patients in NYHA class II, who
were implanted on the basis of preliminary evidence in favour of
the beneﬁcial effect of CRT in subjects with mild heart failure
................................................. .................................................
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Table 5 Univariate and multivariate analysis of factors predicting death from any cause or urgent heart transplantation
in patients with valvular heart disease and dilated cardiomyopathy (n 5 743)
Univariate analysis Multivariate aalysis
HR 95% CI P-value HR 95% CI P-value
Valvular heart disease 1.6 0.9–2.8 0.082 1.1 0.4–2.9 0.495
Male gender 2.1 1.1–4.0 0.022 1.2 0.5–2.9 0.617
Age 1.1 1.0–1.1 0.038 1.0 1.0–1.1 0.054
Chronic atrial ﬁbrillation (no AVN ablation) 1.9 1.3–3.0 0.012 3.1 1.2–7.8 0.018
Chronic atrial ﬁbrillation (AVN ablation) 0.9 0.6–1.2 0.515 — — —
QRS duration 1.0 0.9–1.0 0.715 — — —
NYHA class 0.8 0.5–1.1 0.163 — — —
LV ejection fraction 0.9 0.9–1.0 0.055 1.0 0.9–1.0 0.169
LVEDD 1.1 1.0–1.1 0.006 1.1 1.0–1.1 0.221
LVESD 1.1 1.0–1.1 0.026 1.1 1.0–1.1 0.330
Mitral regurgitation 1.4 1.0–2.0 0.040 1.4 1.0–1.9 0.498
CRT-D use 1.4 0.8–2.3 0.219 — — —
b-Blockers use 0.5 0.3–0.9 0.010 0.6 0.3–1.1 0.060
AVN, atrioventricular node.
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18,19 often combined with the indication for a deﬁbrillator
for secondary prevention. The pharmacological therapy at enrol-
ment was not optimal, in comparison to prescription rates of
b-blockers and angiotensin-converting enzyme inhibitors or ARB
in randomized controlled trials. This observation is in line with
‘real-world’ surveys and indicates that some gaps still exist
between trials and ‘real-world’ practice, with relatively slow adop-
tion of guidelines for the management of heart failure.
1,2 However,
pharmacological treatment did not present great differences
between the three groups of patients we examined, with regard
to prescription of diuretics, b-blockers, angiotensin-converting
enzyme inhibitors, or ARBs, respectively.
In summary, in a ‘real-world’ registry of patients treated with
CRT, with or without deﬁbrillation capabilities, around 6% of
patients are found to have a valvular heart disease as the
primary and sole cause of heart failure. The analysis of our registry,
where data were prospectively collected, shows that CRT is effec-
tive also in this group of patients, not evaluated by randomized
controlled trials. However, patients with valvular heart disease
treated with CRT present a series of features, in comparison to
patients affected by ischaemic heart disease and dilated cardiomyo-
pathy: (i) a higher prevalence of chronic atrial ﬁbrillation, with
atrioventricular node ablation performed in around half of the
cases; (ii) a similar clinical and echocardiographic proﬁle at baseline;
(iii) a similar improvement of LVEF and a similar reduction in ven-
tricular volumes at 6–12 months; (iv) a favourable clinical response
with an improvement of the clinical composite score at 12 months
similar to that occurring in patients with dilated cardiomyopathy
and more pronounced than that observed in patients with ischae-
mic heart disease; (v) a long-term outcome, in terms of freedom
from death or heart transplantation, similar to patients affected
by ischaemic heart disease and basically more severe than that of
patients affected by dilated cardiomyopathy. Thus, patients with
valvular heart disease treated with CRT appear to present a clinical
beneﬁt, but with some distinct clinical features, as well as an
outcome, that do not precisely overlap any of the two other
groups of patients, for which much more data are currently
available.
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Appendix
Centres and investigators participating in the InSync/InSync ICD
Italian Registry are listed below.
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